Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF)

• Main Authors: Przemysław Żelazny (Author), Joanna Filipczak (Author), Oliwer Sygacz (Author), Sebastian Bróż (Author), Sara Dankiewicz (Author), Aleksandra Swora (Author), Joanna Borowik (Author), Wojciech Brodowski (Author), Piotr Pawłowski (Author), Katarzyna Basta-Arciszewska (Author)
• Format: Book
• Published: Kazimierz Wielki University, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Heart failure affects an estimated 23 million people, as many as 50% of whom suffer from a heart failure with reduced ejection fraction (HFrEF), in which the left ventricle ejection fraction is <40% and is accompanied by clinical symptoms. Given the high mortality rate in this group...